Characterization of α-l-Iduronidase (Aldurazyme®) and its complexes

Journal of Proteomics

Volumn 80, Issue , 2013, Pages 26-33

  Jung, Gangsoo ^a   Pabst, Martin ^b,c   Neumann, Laura ^b   Berger, Angelika ^a   Lubec, Gert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c ETH ZURICH   (Switzerland)

Author keywords

l Iduronidase; Glycosylation; Mass spectrometry; Mucopolysaccharide; Mucopolysaccharidosis type I; Post translational modification

Indexed keywords

HISTIDINE; LARONIDASE; LEVO IDURONIDASE; GLYCOPEPTIDASE; OLIGOSACCHARIDE; PHOSPHATASE; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; COMPLEX FORMATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME ANALYSIS; FLUOROMETRY; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN METHYLATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TWO DIMENSIONAL GEL ELECTROPHORESIS; BRAIN; CHEMISTRY; GLYCOSYLATION; HUMAN; IMMUNOCHEMISTRY; LILIACEAE; METABOLISM; METHYLATION; PATHOLOGY; PHOSPHORYLATION; TANDEM MASS SPECTROMETRY;

BRAIN; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GLYCOSYLATION; HUMANS; IDURONIDASE; IMMUNOCHEMISTRY; LILIACEAE; MASS SPECTROMETRY; METHYLATION; OLIGOSACCHARIDES; PEPTIDE-N4-(N-ACETYL-BETA-GLUCOSAMINYL) ASPARAGINE AMIDASE; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84873666745     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.09.022     Document Type: Article

References (28)

1. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123:229-240.
2. Valayannopoulos V., Wijburg F.A. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 2011, 50(Suppl. 5):v49-v59.
3. Neufeld E.F., Muenzer J. The mucopolysaccharides. The metabolic and molecular bases of inherited disease 2001, 3421-3452. McGraw-Hill, Medical Publishing Division, New York, NY, USA. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler (Eds.).
4. Coutinho M.F., Lacerda L., Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int 2012, 2012:471325.
5. Wraith J.E. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 2001, 24:245-250.
6. Colavita N., Orazi C., Fileni A., Leone P.C., Ricci R., Segni G. A further contribution to the knowledge of mucopolysaccharidosis I H/S compound. Presentation of two cases and review of the literature. Australas Radiol 1986, 30:142-149.
7. Roubicek M., Gehler J., Spranger J. The clinical spectrum of alpha-l-iduronidase deficiency. Am J Med Genet 1985, 20:471-481.
8. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001, 344:182-188.
9. Kakkis E.D., Schuchman E., He X., Wan Q., Kania S., Wiemelt S., et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001, 72:199-208.
10. Valayannopoulos V., Boddaert N., Barbier V., Le Merrer M., Caillaud C., de Lonlay P. Cognitive and neuroradiological improvement in three patients with attenuated MPS I treated by laronidase. Mol Genet Metab 2010, 100:20-23.
11. Zhao K.W., Faull K.F., Kakkis E.D., Neufeld E.F. Carbohydrate structures of recombinant human alpha-l-iduronidase secreted by Chinese hamster ovary cells. J Biol Chem 1997, 272:22758-22765.
12. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005, 20(Suppl. 6):vi 3-9.
13. Jefferis R. Aggregation, immune complexes and immunogenicity. MAbs 2011, 3:503-504.
14. Manning M.C., Patel K., Borchardt R.T. Stability of protein pharmaceuticals. Pharm Res 1989, 6:903-918.
15. Sauerborn M., Brinks V., Jiskoot W., Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010, 31:53-59.
16. Kakavanos R., Turner C.T., Hopwood J.J., Kakkis E.D., Brooks D.A. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 2003, 361:1608-1613.
17. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
18. John J.P., Oh J.E., Pollak A., Lubec G. Identification and characterisation of arsenite (+3 oxidation state) methyltransferase (AS3MT) in mouse neuroblastoma cell line N1E-115. Amino Acids 2008, 35:355-358.
19. Kang S.U., Fuchs K., Sieghart W., Pollak A., Csaszar E., Lubec G. Gel-based mass spectrometric analysis of a strongly hydrophobic GABAA-receptor subunit containing four transmembrane domains. Nat Protoc 2009, 4:1093-1102.
20. Chen W.Q., Priewalder H., John J.P., Lubec G. Silk cocoon of Bombyx mori: proteins and posttranslational modifications-heavy phosphorylation and evidence for lysine-mediated cross links. Proteomics 2010, 10:369-379.
21. Pabst M., Bondili J.S., Stadlmann J., Mach L., Altmann F. Mass + retention time = structure: a strategy for the analysis of N-glycans by carbon LC-ESI-MS and its application to fibrin N-glycans. Anal Chem 2007, 79:5051-5057.
22. Pabst M., Grass J., Fischl R., Leonard R., Jin C., Hinterkorner G., et al. Nucleotide and nucleotide sugar analysis by liquid chromatography-electrospray ionization-mass spectrometry on surface-conditioned porous graphitic carbon. Anal Chem 2010, 82:9782-9788.
23. Chen W.Q., Salmazo A., Myllykoski M., Sjoblom B., Bidlingmaier M., Pollak A., et al. Purification of recombinant growth hormone by clear native gels for conformational analyses: preservation of conformation and receptor binding. Amino Acids 2010, 39:859-869.
24. Ghafari M., Hoger H. Keihan Falsafi S, Russo-Schlaff N, Pollak A, Lubec G. Mass spectrometrical identification of hippocampal NMDA receptor subunits NR1, NR2A-D and five novel phosphorylation sites on NR2A and NR2B. J Proteome Res 2012, 11:1891-1896.
25. Robbins A.R., Myerowitz R. The mannose 6-phosphate receptor of Chinese hamster ovary cells. Compartmentalization of acid hydrolases in mutants with altered receptors. J Biol Chem 1981, 256:10623-10627.
26. Tsukimura T., Tajima Y., Kawashima I., Fukushige T., Kanzaki T., Kanekura T., et al. Uptake of a recombinant human alpha-l-iduronidase (laronidase) by cultured fibroblasts and osteoblasts. Biol Pharm Bull 2008, 31:1691-1695.
27. Yogalingam G., Guo X.H., Muller V.J., Brooks D.A., Clements P.R., Kakkis E.D., et al. Identification and molecular characterization of alpha-l-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum Mutat 2004, 24:199-207.
28. Clements P.R., Brooks D.A., Saccone G.T., Hopwood J.J. Human alpha-l-iduronidase. Purification, monoclonal antibody production, native and subunit molecular mass. Eur J Biochem 1985, 152:21-28.